MedTrace Logo

Perioperative Use of Desmopressin (DDAVP) in Breast Cancer

NCT01606072 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2015-08-28

No results posted yet for this study

Summary

The propose for this study is to evaluate the safety and tolerability of desmopressin when administered perioperatively to patients with breast cancer undergoing surgery as first treatment, and select the optimum dose for the clinical development of the product.

Conditions

Interventions

DRUG

Desmopressin

20 patients in 5 groups 4 each, advancing progressively to each dose level.

Sponsors & Collaborators

  • Laboratorio Elea Phoenix S.A.

    lead INDUSTRY

Principal Investigators

  • Dra. Ruth Weinberg · Hospital Interzonal General De Agudos Eva Peron

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2015-02-28
Completion
2015-07-31

Countries

  • Argentina

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01606072 on ClinicalTrials.gov